INmune Bio receives MHRA pediatric plan approval for Ebstrocel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
June 25, 2026 7:00 AM EDTApproval of pediatric strategy validates clinical data package and accelerates the regulatory path for CORDStrom in the United Kingdom
BOCA RATON, Fla, June 25, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the Company), a late-stage biotechnology company focused on inflammation and immunology, today announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the Pediatric Investigation Plan (PIP) for Ebstrocel for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB).
The approval of the PIP is the first required stage toward a Marketing Authorization Application... More
